Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vitreo-Retinal Associates, Michigan
• Collaborator: Van Andel Research Institute
• Treatments: Bevacizumab; Mitogens; Ranibizumab

Criteria

Inclusion Criteria:

• Male or female age 18 to 85 with diabetes and hemoglobin A1Cmacular degeneration.

• Diabetic macular edema with average retinal thickness central subfield >/= 290um.

Exclusion Criteria:

• Macular atrophy/fibrosis.

• Ocular anti-VEGF treatment within 3 months.

• Treatment with topical or oral carbonic-anhydrase inhibitor within one month

• Laser photocoagulation within 3 months (diabetic cohort)